August 7, 2024News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA,…
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic…
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food…
STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…
Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total…
Survey of C-Suite leaders highlights why life sciences commercial model requires an urgent shift SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/…
Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the…
Figure 1 Combination of dulaglutide (Trulicity®) and buntanetap improves memory and synaptic plasticity in AD mice (*p<0.05, **p<0.01). Figure 2…
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025…
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024…